A Landscape of Pharmacogenomic Interactions in Cancer.
Cell
166:
2016
740-754
|
999
|
Assessment of pharmacogenomic agreement.
F1000Res
5:
2016
825
|
18
|
Revisiting inconsistency in large pharmacogenomic studies.
F1000Res
5:
2016
2333
|
45
|
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
Nat Commun
9:
2018
2024
|
54
|
Genetic and transcriptional evolution alters cancer cell line drug response.
Nature
560:
2018
325-330
|
429
|
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.
BMC Genomics
19:
2018
604
|
45
|
The germline genetic component of drug sensitivity in cancer cell lines.
Nat Commun
9:
2018
3385
|
28
|
An RNAi screen in human cell lines reveals conserved DNA damage repair pathways that mitigate formaldehyde sensitivity.
DNA Repair (Amst)
72:
2018
1-9
|
8
|
Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects.
Genome Biol
20:
2019
27
|
24
|
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature
569:
2019
503-508
|
1582
|
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.
Nat Commun
10:
2019
2198
|
62
|
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
Nat Commun
10:
2019
2674
|
138
|
Copy number variation is highly correlated with differential gene expression: a pan-cancer study.
BMC Med Genet
20:
2019
175
|
128
|
Chromosome arm aneuploidies shape tumour evolution and drug response.
Nat Commun
11:
2020
449
|
52
|
Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns.
Sci Adv
6:
2020
eaba1862
|
35
|
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens.
Patterns (N Y)
1:
2020
100065
|
5
|
A first-generation pediatric cancer dependency map.
Nat Genet
53:
2021
529-538
|
68
|
Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines.
Elife
10:
2021
e66198
|
7
|
Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response.
Int J Mol Sci
22:
2021
10135
|
2
|
Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
BMC Med
20:
2022
175
|
4
|
Mutational signatures are markers of drug sensitivity of cancer cells.
Nat Commun
13:
2022
2926
|
28
|
CNpare: matching DNA copy number profiles.
Bioinformatics
38:
2022
3638-3641
|
2
|